SUNNY PHARMTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.25 TWD | +2.06% |
|
+4.41% | -20.90% |
| 04-18 | Sunny Pharmtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Sunny Pharmtech Inc.(TPEX:6676) added to S&P Global BMI Index | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 2,736 | 5,117 |
| Enterprise Value (EV) 1 | 3,027 | 5,237 |
| P/E ratio | -16.1 x | -78.3 x |
| Yield | - | - |
| Capitalization / Revenue | 7.61 x | 11.9 x |
| EV / Revenue | 8.42 x | 12.2 x |
| EV / EBITDA | -36.4 x | 107 x |
| EV / FCF | -25,572,891 x | -50,355,990 x |
| FCF Yield | -0% | -0% |
| Price to Book | 2.82 x | 4.29 x |
| Nbr of stocks (in thousands) | 138,525 | 148,525 |
| Reference price 2 | 19.75 | 34.45 |
| Announcement Date | 4/11/23 | 4/18/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 142.8 | 234.5 | 419.9 | 241 | 359.6 | 428.8 |
| EBITDA 1 | -220.7 | -120.9 | 26.9 | -76.24 | -83.09 | 49.13 |
| EBIT 1 | -299 | -214 | -74.34 | -176 | -187.6 | -72.1 |
| Operating Margin | -209.39% | -91.28% | -17.7% | -73.03% | -52.18% | -16.81% |
| Earnings before Tax (EBT) 1 | -299.6 | -226.3 | -101.8 | -174.8 | -170.2 | -63.32 |
| Net income 1 | -299.6 | -226.3 | -101.8 | -174.8 | -170.2 | -63.32 |
| Net margin | -209.8% | -96.51% | -24.23% | -72.53% | -47.34% | -14.77% |
| EPS 2 | -2.680 | -1.800 | -0.7900 | -1.310 | -1.230 | -0.4400 |
| Free Cash Flow | - | -113.3 | -51.13 | -157.7 | -118.4 | -104 |
| FCF margin | - | -48.34% | -12.18% | -65.42% | -32.92% | -24.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/9/20 | 4/9/20 | 4/8/22 | 4/8/22 | 4/11/23 | 4/18/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 158 | 52.9 | 142 | 125 | 292 | 121 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.7161 x | -0.4377 x | 5.29 x | -1.637 x | -3.509 x | 2.458 x |
| Free Cash Flow | - | -113 | -51.1 | -158 | -118 | -104 |
| ROE (net income / shareholders' equity) | - | -20.9% | -9.29% | -16.1% | -16.2% | -5.84% |
| ROA (Net income/ Total Assets) | - | -8.77% | -2.98% | -7.11% | -7.27% | -2.7% |
| Assets 1 | - | 2,580 | 3,414 | 2,458 | 2,341 | 2,348 |
| Book Value Per Share 2 | 9.120 | 8.850 | 8.070 | 8.130 | 7.000 | 8.040 |
| Cash Flow per Share 2 | 1.340 | 2.280 | 1.870 | 1.650 | 1.610 | 1.810 |
| Capex 1 | 264 | 78.9 | 65 | 159 | 179 | 144 |
| Capex / Sales | 184.61% | 33.63% | 15.48% | 65.96% | 49.83% | 33.58% |
| Announcement Date | 4/9/20 | 4/9/20 | 4/8/22 | 4/8/22 | 4/11/23 | 4/18/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.90% | 124M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 6676 Stock
- Financials Sunny Pharmtech Inc.
